NCT07154238Enrolling By Invitation不适用
Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.
适应症
试验速览
- 阶段
- 不适用
- 状态
- Enrolling By Invitation
- 入组人数
- 2,546
- 试验地点
- 1
- 主要终点
- Description of characteristics, including clinical, demographic and physical characteristics, among individuals initiated on injectable semaglutide for weight management
研究概览
简要总结
The purpose of this study is to collect information for scientific research and to better understand the experiences of participants managing their weight. The study aims to collect valid responses through online interviews from participants. This study is a survey-based study without collection of laboratory data. Duration of the study will be about 14 months.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •For an eligible participant (individuals initiated on injectable semaglutide for weight management), all inclusion criteria must be answered "yes".
- •Electronically provided consent obtained before any study-related activities can be completed.
- •Age above or equal to 18 years at the time of providing informed consent.
- •Reside in a participating country: Australia, Germany, United Arab Emirates (UAE) and Spain.
- •Have been prescribed and initiated injectable semaglutide for weight management prior to study screening.
- •For an eligible participant (HCPs), all inclusion criteria must be answered "yes".
- •Electronically provided consent obtained before any study-related activities can be completed.
- •Practice in a participating country: Australia, Germany, UAE, and Spain.
- •See at least 150 patients for any condition per month; priority given to those who treat at least 200 patients for any condition per month.
- •Treat at least 10 adult patients per month for weight management.
- •Prescribe anti-obesity medications (AOMs) to their patients they personally treat for weight management/obesity care; priority given to those who treat at least 10% of the patients they personally treat for weight management/obesity care with anti-obesity medications (AOMs).
- •Prescribe injectable semaglutide for weight management.
- •Be a specialty of interest (varies by country); mix of primary care, specialists such as Endocrinologists, Diabetologists, Nutrition Specialists, Obesity Specialists and others.
排除标准
- •For an eligible participant (individuals initiated on injectable semaglutide for weight management), all exclusion criteria must be answered "no".
- •Unwillingness or language barriers precluding adequate understanding or cooperation.
- •Is currently or planning to become pregnant in next six months.
- •Is taking injectable semaglutide for Type 2 diabetes management only.
- •For an eligible participant (HCPs), all exclusion criteria must be answered "no".
- •Prior participation in this study. Participation is defined as having given informed consent and submitting responses to an interview.
- •Unwillingness or language barriers precluding adequate understanding or cooperation.
- •Only treats patients under 18 years of age.
结局指标
主要结局
Description of characteristics, including clinical, demographic and physical characteristics, among individuals initiated on injectable semaglutide for weight management
时间窗: At the time of survey response (Day 1)
Patient Quantitative Segment Multi select from a defined list Single select from a defined list Numeric entry Open-ended type-in Patient Qualitative Segment Open-ended commentary
Individual-reported change in BMI since initiation
时间窗: At the time of survey response (Day 1)
Patient Quantitative Segment Numeric entry (BMI calculated based on self-reported height and weight)
Description of the experience of individuals initiated on injectable semaglutide for weight management through personal perception of physical and mental health and self-reported QoL
时间窗: At the time of survey response (Day 1)
Patient Quantitative Segment 7-point Likert scale for agreement (where 1 indicates extremely dissatisfied and 7 indicates extremely satisfied) Single select from a defined list EQ-5D-5L Patient Qualitative Segment Open-ended commentary
Individual-reported achievement of weight loss goal
时间窗: At the time of survey response (Day 1)
Patient Quantitative Segment Yes/No; percentage of weight loss goal achieved Patient Qualitative Segment Open-ended commentary
Individual-reported change in weight since initiation
时间窗: At the time of survey response (Day 1)
Patient Quantitative Segment Numeric entry in (kgs); percentage of weight change Patient Qualitative Segment Open-ended commentary
Individual-reported changes in daily life since initiation on injectable semaglutide
时间窗: At the time of survey response (Day 1)
Patient Qualitative Segment Open-ended commentary
次要结局
- Satisfaction with weight loss since initiation(At the time of survey response (Day 1))
- Treatment expectation of individuals initiated on injectable semaglutide of ability to achieve weight loss goal using injectable semaglutide(At the time of survey response (Day 1))
- Expectation for length of time of treatment to desired result from date of initiation on injectable semaglutide at baseline(At the time of survey response (Day 1))
- Expectation of individuals initiated on injectable semaglutide for weight management who believe they will have greater success in achieving their weight loss with the use of injectable semaglutide(At the time of survey response (Day 1))
- Expected benefits of injectable semaglutide(At the time of survey response (Day 1))
- Overall satisfaction with injectable semaglutide(At the time of survey response (Day 1))
- Individual-reported changes in perception of injectable semaglutide since initiation(At the time of survey response (Day 1))
- Attitudes of individuals related to obesity or weight related stigmatization or discrimination prior to/since/due to initiation on injectable semaglutide(At the time of survey response (Day 1))
- Attitudes of individuals initiated on injectable semaglutide for weight management related to obesity as a chronic disease(At the time of survey response (Day 1))
- Attitudes of individuals initiated on injectable semaglutide for weight management related to weight loss being their responsibility(At the time of survey response (Day 1))
- Attitudes of individuals initiated on injectable semaglutide for weight management related to weight loss being more likely with use of prescription medication for weight loss (AOMs)(At the time of survey response (Day 1))
- Degree of knowledge of individuals initiated on injectable semaglutide for weight management related to how prescription weight loss medications (AOMs) work in the body(At the time of survey response (Day 1))
- Behaviours of individuals initiated on injectable semaglutide for weight management related to making lifestyle changes in addition to initiating on injectable semaglutide for weight loss or weight management to achieve their weight loss goals(At the time of survey response (Day 1))
- Attitudes of individuals initiated injectable semaglutide for weight management related to the necessity to make lifestyle changes in addition to initiating injectable semaglutide for weight loss or weight management to achieve their weight loss goals(At the time of survey response (Day 1))
- Attitudes of individuals who initiated on injectable semaglutide for weight management relating to ease of maintaining lifestyle changes (e.g., eating a healthy diet and getting regular exercise) since initiating on injectable semaglutide(At the time of survey response (Day 1))
- Individual-reported change in overall knowledge of how AOMs work from initiation on injectable semaglutide to present day(At the time of survey response (Day 1))
- Attitudes related to viewing obesity as a chronic disease(At the time of survey response (Day 1))
- Attitudes related to belief weight loss is solely an individual's responsibility(At the time of survey response (Day 1))
- Attitudes related to belief weight loss requires use of prescription medication for weight loss (AOMs)(At the time of survey response (Day 1))
- Attitudes related to belief individuals must make lifestyle changes in addition to initiating on injectable semaglutide for weight loss or weight management to achieve their weight loss goals(At the time of survey response (Day 1))
- Attitudes related to belief individuals will have greater success in achieving their weight loss goals with use of injectable semaglutide(At the time of survey response (Day 1))
- Attitudes related to level of comfort prescribing AOMs and injectable semaglutide specifically for weight management(At the time of survey response (Day 1))
- Reasons for length of adherence(At the time of survey response (Day 1))
- Future planned use of injectable semaglutide (among current users)(At the time of survey response (Day 1))
- Reasons for discontinuation (among those who discontinued)(At the time of survey response (Day 1))
- Likelihood to resume injectable semaglutide (specifically for weight management) after formal discontinuation and reasons(At the time of survey response (Day 1))
- Individual-reported likelihood of continuation on injectable semaglutide until achieve goal weight and reasons(At the time of survey response (Day 1))
- Likelihood of continuation on injectable semaglutide after achieving weight loss goal and reasons(At the time of survey response (Day 1))
- Treatment pause initiated by individual and reasons(At the time of survey response (Day 1))
- Treatment pause initiated by HCP and reasons(At the time of survey response (Day 1))
- Number of treatment pauses(At the time of survey response (Day 1))
- Among those with low likelihood to use injectable semaglutide after discontinuation, potential use of another AOM(At the time of survey response (Day 1))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Study to Assess Treatment Patterns, Clinical Outcomes and Healthcare Resource Utilization Among Adult Participants With Moderate-To-Severe Plaque PsoriasisPsoriasisNCT05547490Bristol-Myers Squibb3,506
已完成
不适用
A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in CanadaHereditary Angioedema (HAE)AngioedemaNCT05578417Takeda60
已完成
不适用
A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.Metastatic Breast CancerNCT04671615Pfizer559
已完成
不适用
A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at HomeHereditary Angioedema (HAE)NCT05489640Takeda85
已完成
不适用
Patient Characteristics, Treatment Patterns And Incidence Of Events (Discontinuation, Persistence, Key Primary Clinical Outcomes) In NVAF Patients Initiating OAC Therapy In ColombiaAtrial FibrillationNCT04234698Pfizer2,076